除菌後胃がんを見逃さない！　H.pylori既感染者の胃内視鏡診断アトラス

出版社： 金芳堂
著者：
発行日： 2021-04-26
分野： 臨床医学：内科  >  消化器一般
ISBN： 9784765318662
電子書籍版： 2021-04-26 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,480 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,480 円(税込)

購入する

商品紹介

H.pylori除菌後の胃がんを見落とさないための目と頭を養う内視鏡診断アトラスです。
H.pylori除菌治療の保険適用拡大（2013年）に伴い、既感染患者の胃粘膜・除菌後胃がんの所見に出会う機会が増えています。ただ、スクリーニングを行う施設でそれらを十分にフォローできていないことも現状です。スクリーニングで胃がんリスクが高いH.pylori現感染例の内視鏡観察は引き続き重要ですが、増加しているH.pylori除菌後例に対応する術を持っておく必要があるでしょう。
本書では、既感染患者の胃粘膜を内視鏡で的確にスクリーニングするために、判断に迷う症例や見逃しがちな症例を写真を中心に紹介しています。「このような所見なら注意が必要なのか！」と新たな発見があったり、改めて学んだりすることのできる参考書です。

目次

  • I章　H.pylori感染と胃粘膜状態の変遷
    1　スクリーニング検査でみられる胃粘膜状態
    ≫　A　「胃炎の京都分類」からみた人間ドック受診者の胃粘膜状態に関する検討
    ≫　B　人間ドック受診者の胃粘膜状態（総合病院健診センターでの検討）
    ≫　C　対策型内視鏡検診における胃粘膜状態
    －　Note1　胃がんリスク層別化検査：ABC（D）分類の各群の占める割合の時代的変遷

    2　スクリーニング検査で発見された胃がんの胃粘膜状態
    ≫　A　人間ドックにおけるH.pylori感染状態と発生胃がん
    ≫　B　人間ドック・健診・検診で発見された胃がんの胃粘膜状態

    II章　除菌後にみられる胃粘膜と胃がん発生リスク
    1　除菌後の内視鏡所見と組織学的変化
    ≫　A　びまん性発赤の改善について
    ≫　B　体部小彎の萎縮粘膜について
    ≫　C　地図状発赤・斑状発赤の所見について
    ≫　D　除菌後にみられる胃底腺ポリープ様隆起
    ≫　E　組織学的胃炎の改善状況
    －　Note2　除菌後の胃X線像の特徴―これを見れば、除菌後胃粘膜だ！
    －　Note3　除菌後の血清マーカー（ペプシノゲン、ガストリン、H.pylori抗体）

    2　除菌後の胃がん発生リスク
    ≫　A　除菌による早期胃がん内視鏡治療後の二次がん発生低下
    ≫　B　胃がんの既往歴のないH.pylori感染者（消化性潰瘍の既往を含む）に対する除菌による胃がん発生の抑制効果

    III章　除菌後胃がんの特徴と内視鏡観察のコツ
    1　除菌後胃がん発生のリスク
    ≫　A　除菌前の胃粘膜状態で除菌後胃がん発生リスクが予測できるか？
    ≫　B　除菌後の胃粘膜状態で胃がん発生リスクが予想できるか？

    2　除菌後胃がんと現感染胃がんの比較
    ≫　A　除菌後に発見される胃がんの特徴
    ≫　B　除菌後に発見される胃がんの特徴（分化型がんを中心に）
    ≫　C　除菌後に発見される胃がんの特徴（未分化型がんも含めて）
    ≫　D　除菌後に発見される進行がん

    3　除菌後胃がんを見逃さないためのコツ
    ≫　A　検診・総合健診におけるスクリーニング検査
    ≫　B　経鼻内視鏡によるスクリーニング検査
    ≫　C　LCI（linked color imaging）、BLI（blue laser imaging）を用いた観察
    ≫　D　NBI（narrow-band imaging）観察・拡大内視鏡による観察

    IV章　未感染胃がん、その他の内視鏡所見
    1　未感染胃がんの特徴と内視鏡所見
    ≫　A　褪色調を呈する印環細胞がん
    ≫　B　胃底腺型胃癌
    ≫　C　食道胃接合部がん（Barrett腺がんを除く）
    ≫　D　ラズベリー様腺窩上皮型胃がん

    2　H.pylori以外の原因による胃炎と腫瘍性病変
    ≫　A　NHPH（Non-Helicobacter pylori Helicobacters）感染による胃炎と腫瘍性病変
    ≫　B　自己免疫性胃炎（A型胃炎）と腫瘍性病変

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 H. pylori感染と胃粘膜状態の変遷

P.9 掲載の参考文献
1) 鎌田智有. 第2章 胃炎の内視鏡所見-1. 総論. 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類. 日本メディカルセンター, 2014 : 25-29.
 
2) 国立がん研究センターがん予防・検診研究センター. 有効性評価に基づく胃がん検診ガイドライン 2016年版. 2015, https://www.ncc.go.jp/jp/information/pr_release/2015/0420/index.html
 
3) Kimura K, et al. An endoscopic recognition of atrophic border and its significance in chronic gastritis. Endoscopy. 1969 ; 1 : 87-97.
 
4) Tytgat GN. The Sydney System : endoscopic division. J Gastroenterol Hepatol. 1991 ; 6 : 223-234.
PubMed
5) Price AB. The Sydney System : histological division. J Gastroenterol Hepatol. 1991 ; 6 : 209-222.
PubMed
6) 望月直美, 他. 健診の内視鏡検査におけるHelicobacter pylori感染診断. Helicobacter Research. 2015 ; 19 : 41-46.
 
7) Ueda J, et al. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter. 2014 ; 19 : 105-110.
 
8) Kamada T, et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 2015 ; 20 : 192-198.
PubMed
9) Tsuda M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017 ; 22 : e12415.
 
10) Fukase K, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer ; an open-label, randomized trial. Lancet. 2008 ; 372 : 392-397.
PubMed
11) Kamada T, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori : results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol fier. 2005 ; 21 : 1121-1126.
 
12) Moribata K, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication. Dig Endosc. 2016 ; 28 : 434-442.
PubMed
13) 鎌田智有, 他. 胃炎の京都分類と胃癌のスペクトラム. 消化器内視鏡. 2018 ; 30 : 46-49.
Medical*Online
P.16 掲載の参考文献
1) 最新がん統計. 国立がん研究センターがん情報サービス, 最新がん統計, 2020.
 
2) 上村直美, 他. 「ヘリコバクター・ピロリ除菌の保険適用による胃がん減少効果の検証」. 厚生労働科学特別研究事業報告, 2017.
 
3) 小林正夫, 他. ヘリコバクターピロリ除菌時代における胃がん検診への提言. 日消がん検診誌. 2019 ; 57 : 1114-1127.
 
4) 木村光政, 他. 9年間の胃がん症例からみた胃がん検診対象年齢の検討. 日消がん検診誌. 2016 ; 54 : 259-269.
 
5) 加藤元嗣, 他. 「Helicobacter pylori感染の疫学」. 日内会誌. 2017 ; 106 : 10-15.
 
6) 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類 改訂第2版. 日本メディカルセンター, 2014.
 
P.25 掲載の参考文献
1) 入口陽介. 胃がん検診の歴史と今後の展望. 胃と腸. 2018 ; 53 : 1069-1072.
 
2) 中村裕一, 他. 福岡市の胃がん内視鏡個別検診の成績 X線個別検診および集団検診との比較検討. 日消集検誌. 2004 ; 42 : 489-497.
 
3) 北川晋二. 福岡市医師会胃癌個別検診の現状と問題点. 日消がん検診誌. 2009 ; 47 : 9-27.
 
4) 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類 改訂第2版. 日本メディカルセンター. 2018.
 
5) 井上和彦, 他. 「胃炎の京都分類」の内視鏡所見-スクリーニング内視鏡における活用を含めて-. Gastroenterol Endosc. 2017 ; 59 : 458-464.
 
6) 古川敬一, 他. 胃癌スクリーニングとしての内視鏡検査の現状と問題点. 住民個別検診の立場から. 胃と腸. 2008 ; 43 : 1153-1163.
 
7) 大野健次, 他. 金沢市対策型内視鏡検診における逐年発見胃がんの検討 (ガイドラインへの提言). 日消がん検診誌. 2020 ; 58 : 271-279.
 
8) Maehata Y, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012 ; 75 : 39-46.
PubMed
9) Ito M, et al. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Aliment Pharmacol fier. 2005 ; 21 : 559-566.
 
P.29 掲載の参考文献
1) 井上和彦. ペプシノゲン法の近年の研究動向・ヘリコバクターピロリ菌とペプシノゲン法-総合健診での検討-. 三木一正, 編. ペプシノゲン法. 医学書院, 1998. 196-200.
 
2) 井上和彦, 他. 血清ペプシノゲン法とヘリコバクターピロリ抗体価を用いた胃の "健康度" 評価-同日に行った内視鏡検査を基準として-. 日本消化器集団検診学会雑誌. 2005 ; 43 : 332-339.
 
3) Inoue K, et al. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Biol Markers. 2010 ; 25 : 207-212.
PubMed
4) 井上和彦, 他. ABC分類の有用性と問題点-ペプシノゲンの正常値の検討も含めて-. Helicobacter Res. 2011 ; 15 : 422-427.
 
5) Inoue K. Stratification of gastric cancer risk by H. pylori infection. In : Suzuki H, et al (ed), Helicobacter pylori, Springer Japan, 2016. 169-179.
 
6) Terasawa T, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in eastern Asians : a systematic review and meta-analysis. PLoS One. 2014 ; 9 : e109783.
PubMed
7) Miki K, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroentereol Jpn. 1987 ; 22 : 133-141.
PubMed
8) 井上和彦, 他. 胃の "健康度" 評価 (ABC (D)) 分類におけるHelicobacter pylori除菌後例の表記に関する提案. 日ヘリコバクター会誌. 2012 ; 14 : 18-23.
 
9) 近藤隆則, 他. 中学生Helicobacter pylori検診と除菌治療-真庭市における3年間の成績-, 日本ヘリコバクター学会誌. 2017 ; 18 : 14-20.
 
P.38 掲載の参考文献
1) Kamada T, et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 2015 ; 20 : 192-198.
PubMed
2) International agency for research on cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. 1994 ; 61 : 177-240.
 
3) Uemura N, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 ; 345 ; 784-789.
PubMed
4) Fukase K, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomized controlled trial. Lancet. 2008 ; 372 : 392-397.
PubMed
5) Lee YC, et al. Association between Helicobacter pylori eradication and gastric cancer incidence : A systematic review and meta-analysis. Gastroenterology. 2016 ; 150 : 1113-1124.
PubMed
6) 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類 改訂第2版. 日本メディカルセンター. 2018.
 
7) 吉村理江, 他. 「胃炎の京都分類」を日常診療でいかに使うか. Part 4. 胃炎の京都分類を使用してみて. 3. 検診の立場から. Helicobacter Research. 2016 ; 20 : 372-375.
 
8) 春間賢, 他. Helicobacter pylori除菌後10年以上経過して発見された胃癌症例の検討. 胃と腸. 2012 ; 47 : 1623-1629.
 
9) Matsuo T, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011 ; 16 : 415-419.
PubMed
10) Ono S, et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in Japanese endoscopic submucosal dissection series including histological, endoscpic and serological atrophy. Digestion. 2012 ; 86 : 59-65.
 
11) 藤崎順子, 他. Helicobacter pylori陰性未分化型早期胃癌の特徴. 胃と腸. 2014 ; 49 : 854-861.
 
12) Yoshimura D, et al. Clinical and pathological characteristics of gastric cancer without Helicobacter pylori infection and its background gastric mucosa. Gastroenterology. 2017 ; 152 : S260-261.
 
13) 吉村大輔, 他. H. pylori未感染胃癌-現状と未来の課題. 胃と腸. 2018 ; 53 : 658-670.
 
14) 鈴木翔, 他. H. pylori未感染胃上皮性腫瘍の臨床的特徴. 胃と腸. 2020 ; 55 : 981-987.
 
15) 青木利佳, 他. 検診施設におけるHelicobacter pylori未感染胃癌の時代的変遷. 胃と腸. 2014 ; 49 : 841-853.
 
16) Kamada T, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori : results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005 ; 21 : 1121-1126.
PubMed
17) Saka A, et al. Endoscopic and histological features of gastric cancers after successful Helicobacter pylori eradication therapy. Gastric Cancer. 2016 ; 19 : 524-530.
 
18) Kobayashi M, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol. 2013 ; 48 : 1332-1342.
PubMed
19) Satoshi S, et al. Lincked color imaging for the detection of early gastrointestinal neoplasms. Therap Adv Gastroenterol. 2019 ; 12 : 1756284819885246.
 
20) Yagi K, et al. Green epithelium revealed by narrow-band imaging (NBI) : A feature for practical assessment of extent of gastric cancer after H. pylori eradication. Endoscopy. 2018 ; IO 06 : E1289-E1295.
 
21) Take S, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020 ; 55 : 281-288.
PubMed
22) 小林正明, 他. 除菌後に発見される胃浸潤がんの特徴. 消化器内科. 2020 ; 2 : 59-66.
 
23) 吉村大輔, 他. 消化管腫瘍の内視鏡診断 2020. 上皮性悪性腫瘍の診断 (H. pylori未感染胃癌). 胃と腸. 2020 ; 55 : 572-583.
 
P.49 掲載の参考文献
1) International agency for research on cancer. IARC monographs on the evaluation of carcinogenetic risks to humans. Schistosomes, liver flukes and Helicobacter pylori. 1994 ; 61 : 218-220.
 
2) Herrero R, et al. The fight against gastric cancer-the IARC Working Group report. Best Pract Res Clin Gastroenterol. 2014 ; 28 : 1107-1114.
 
3) Uemura N, et al. Effect of Helicobacter pylori infection on subsequent development of cancer after endoscopic resection of gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997 ; 6 : 639-642.
PubMed
4) Matsuo T, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011 ; 16 : 415-419.
PubMed
5) Fukase K, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early cancer : an open-label, randomized controlled trial. Lancet. 2008 ; 372 : 392-397.
PubMed
6) Ford AC, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals : systematic review and meta-analysis of randomized controlled trials. BMJ. 2014 ; 348 : g3174.
PubMed
7) Kamada T, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori : results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005 ; 21 : 1121-1126.
PubMed
8) Take S, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 2011 ; 46 : 318-324.
 
9) Take S, et al. Baseline gastric mucosal atrophy is a risk factor associated with Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007 ; 42 : 21-27.
PubMed
10) 鎌田智有, 他. 除菌後発見胃癌の臨床的特徴-除菌後10年未満と10年以上で発見された胃癌の比較-. 胃と腸. 2016 ; 51 : 750-758.
 
11) 春間賢, 他. Helicobacter pylori除菌後10年以上経過して発見された胃癌症例の検討 (多施設共同調査), 胃と腸. 2012 ; 47 : 1623-1629.
 
12) 井上和彦, 他. H. pylori陰性時代の胃癌スクリーニングのあり方. 消化器内視鏡. 2018 ; 30 : 37-46.
Medical*Online

II章 除菌後にみられる胃粘膜と胃がん発生リスク

P.61 掲載の参考文献
1) Nomura S, et al. Endoscopic diagnosis of gastric mucosal activity and inflammation. Dig Endosc. 2013 ; 25 : 136-146.
PubMed
2) 寺尾秀一. びまん性発赤. 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類 改訂2版. 日本メディカルセンター, 2018 : 39-41.
 
3) 寺尾秀一, 他. H. pylori除菌後長期経過による内視鏡像の変化H. pylori除菌後10年以上観察例におけるH. pylori胃炎除菌後内視鏡像の検討および除菌直後と10年以上経過時点でのNBI拡大像の比較. 消化器内科. 2013 ; 57 : 111-118.
 
4) 寺尾秀一, 他. A型胃炎の臨床的・病理学的・内視鏡的特徴とB型胃炎との鑑別, 臨床消化器内科. 2019 ; 34 : 1585-1594.
 
5) 寺尾秀一, 他. 「胃炎の京都分類」の使い方, 重要な所見「発赤」. 消化器内科. 2019 ; 1 : 26-36.
 
6) 寺尾秀一, 他. 胃炎の京都分類 "マスターラーニング" Hp既感染例におけるRACと点状発赤の比較Helicobacter Research. 2020 ; 24. (発刊準備中)
 
7) 寺尾秀一, 他. 8. ピロリ感染以外にびまん性発赤を呈する場合はありますか. 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類. 日本メディカルセンター, 2017 : 27-29.
 
P.69 掲載の参考文献
1) Nakajima S, et al. Incisura angularis belongs to fundic or transitional gland regions in Helicobacter pylori-naive normal stomach : Sub-analysis of the prospective multi-center study. Dig Endosc. 2021 ; 33 : 125-132.
PubMed
2) Dixon MF, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996 ; 20 : 1161-1181.
PubMed
3) Fujishima K, et al. Histopathologic study on development and extension of atrophic change in the gastric mucosa. Gastroenterol Jpn. 1984 ; 19 : 9-17.
 
4) Kimura K, et al. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969 ; 3 : 87-97.
 
5) 榊信広, 他. 腺境界と内視鏡. 竹本忠良, 他編. 消化器内視鏡検査のトピックス. 医学図書出版, 1978 ; 178-183.
 
6) Warren JR, et al. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983 ; 1 : 1273-1275.
PubMed
7) 中島滋美, 他. 組織学的胃炎のtopographyと内視鏡所見. Helicobacter Research. 2009 ; 13 : 74-81.
Medical*Online
8) 森直子, 他. 病理検査を必須としない自己免疫性胃炎診断の妥当性. 日消がん検診誌. 2020 ; 58 : 423-436.
 
9) Masuyama H, et al. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk. Digestion. 2015 ; 91 : 30-36.
PubMed
10) Take S, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020 ; 55 : 281-288.
PubMed
11) Kodama M, et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion. 2012 ; 85 : 126-130.
PubMed
12) 滝澤登一郎. 胃の病理形態学. 医学書院, 2003.
 
13) Rugge M, et al. OLGA staging for gastritis : a tutorial. Dig Liver Dis. 2008 ; 40 : 650-658.
PubMed
14) Uedo N, et al. A new method of diagnosing gastric intestinal metaplasia : narrow-band imaging with magnifying endoscopy. Endoscopy. 2006 ; 38 : 819-824.
PubMed
P.78 掲載の参考文献
1) Nagata N, et al. Predictability of gastric intestinal metaplasia by mottled patchy erythema seen on endoscopy. Gastroenterol Res. 2011 ; 4 : 203-209.
 
2) Uedo N, et al. A new method of diagnosing gastric intestinal metaplasia : narrow-band imaging with magnifying endoscopy. Endoscopy. 2006 ; 38 : 819-824.
PubMed
3) Ono S, et al. Lavender color in linked color imaging enables noninvasive detection of gastric intestinal metaplasia. Digestion. 2018 ; 98 : 222-230.
PubMed
4) Kotachi T, et al. Clinical significance of reddish depressed Lesions observed in the gastric mucosa after Helicobacter pylori eradication. Digestion. 2018 ; 98 : 48-55.
PubMed
5) Yoshii S, et al. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis. Dig Endosc. 2020 ; 32 : 74-83.
 
6) Moribata K, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication. Dig Endosc. 2016 ; 28 : 434-442.
PubMed
7) Majima A, et al. Linked color imaging identifies important risk factors associated with gastric cancer after successful eradication of Helicobacter pylori. Gastrointest Endosc 2019 ; 90 : 763-769.
PubMed
P.88 掲載の参考文献
1) 春間賢, 他. 胃底腺性過形成性ポリープの背景胃粘膜の検討. 日消誌. 1989 ; 86 : 851-857.
 
2) 鎌田智有, 他. 胃ポリープの自然史とmalignant potential-胃底腺ポリープ. 胃と腸. 2012 ; 47 : 1227-1234.
 
3) Hongo M, et al. Gastric Polyps Study Group : incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy : a prospective study in Japan. J Gastroenterol. 2010 ; 45 : 618-624.
 
4) 井上和彦, 他. 胃炎の臨床診断-血清診断. 胃と腸. 2016 ; 51 : 64-71.
 
5) Inoue K, et al. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Biol Markers. 2010 ; 25 : 207-212.
PubMed
6) Yagi K, et al. Characteristic endoscopic and magnified endoscopic findings in the normal stomach without Helicobacter pylori infection. J Gastroenterol Hepatol. 2002 ; 17 : 39-45.
PubMed
7) 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類 改訂第2版. 日本メディカルセンター, 2018.
 
P.99 掲載の参考文献
1) Lee YC, et al. Association between Helicobacter pylori eradication and gastric cancer incidence : A systematic review and meta-analysis. Gastroenterology. 2016 ; 150 : 1113-1124.
PubMed
2) Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer : A systematic review and meta-analysis. Gastric Cancer. 2019 ; 22 : 435-445.
PubMed
3) Murakami K, et al. Long-term monitoring of gastric atrophy and intestinal metaplasia after Helicobacter pylori eradication. Clin J Gastroenterol. 2012 ; 5 : 247-250.
PubMed
4) Dixon MF, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996 ; 20 : 1161-1181.
PubMed
5) Genta RM. Recognizing atrophy : another step toward a classification of gastritis. Am J Surg Pathol. 1996 ; 20 Suppl 1 : S23-30.
 
6) 佐藤貴一. 除菌後萎縮性胃炎の変化について. 日本ヘリコバクター学会誌. 2003 ; 4 : 41-47.
Medical*Online
7) Rokkas T, et al. The long-term impact of Helicobacter pylori eradication on gastric histology : a systematic review and meta-analysis. Helicobacter. 2007 ; 12 Suppl 2 : 32-38.
 
8) Wang J, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication : a meta-analysis. Digestion. 2011 ; 83 : 253-260.
PubMed
9) Kong YJ, et al. Histological changes of gastric mucosa after Helicobacter pylori eradication : a systematic review and meta-analysis. World J Gastroenterol. 2014 ; 20 : 5903-5911.
PubMed
10) Kodama M, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012 ; 47 : 394-403.
PubMed
11) Hwang YJ, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication-a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018 ; 47 : 380-390.
PubMed
12) Choi IJ, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018 ; 378 : 1085-1095.
PubMed
13) 日本ヘリコバクター学会ガイドライン作成委員会編. H. pylori感染の診断と治療のガイドライン 2016改訂版. 先端医学社, 2016.
 
14) Uemura N, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 ; 345 : 784-778.
PubMed
15) Wong BC, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial. JAMA. 2004 ; 291 : 187-194.
 
16) Moribata K, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication. Dig Endosc. 2016 ; 28 : 434-442.
PubMed
17) Shichijo S, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016 ; 84 : 618-624.
PubMed
18) Kodama M, et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol. 2013 ; 48 : 1249-1256.
PubMed
19) Chen HN, et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia : Evidence from a meta-analysis. Gastric Cancer. 2016 ; 9 : 166-175.
 
20) Xia HHX, et al. Aberrant epithelial expression of trefoil family factor 2 and mucin 6 in Helicobacter pylori infected gastric antrum, incisura, and body and its association with antralisation. J Clin Pathol. 2004 ; 57 : 861-866.
 
21) Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulecer, and gastric cancer. World J Gastroenterol. 2014 ; 20 : 5191-5204.
PubMed
22) Goldenring JR. Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia : reparative lineages in the gastrointestinal mucosa. J Pathol. 2018 ; 245 : 132-137.
PubMed
23) Wada Y, et al. Histological changes associated with pyloric and pseudopyloric metaplasia after Helicobacter pylori eradication. Virchows Arch. 2020;477 : 489-496.
PubMed
P.105 掲載の参考文献
1) Itoh T, et al. Correlation between the ABC classification and radiological findings for assessing gastric cancer risk. Jpn J Radiol. 2015 ; 33 : 636-644.
PubMed
2) 山崎道夫, 他. 当院胃X線検診におけるH. pylori除菌治療による画像所見の変化. 日消がん検診誌. 2016 ; 54 : 512-517.
 
3) 萩原武, 他. H. pylori除菌治療後の検診受診者に対する胃X線検査による感染診断の検討-診断精度と問題点-. 日消がん検診誌. 2016 ; 54 : 42-51.
 
4) 伊藤高広, 他. 胃がんX線検診へのヘリコバクター・ピロリ感染に関する問診導入の初期成績. 日消がん検診誌. 2012 ; 50 : 325-331.
 
5) 日本消化器がん検診学会, 他編. 胃X線検診のための読影判定区分アトラス. 2017. 75-82.
 
P.112 掲載の参考文献
1) Samloff IM. Pepsinogens I and II ; Purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology. 1982 ; 82 : 26-33.
PubMed
2) Miki K, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroentereol Jpn. 1987 ; 22 : 133-141.
PubMed
3) 井上和彦, 他. 胃炎の臨床診断-血清診断. 胃と腸. 2016 ; 51 : 64-71.
 
4) 三木一正, 編. 人間ドックにおけるペプシノゲン法・人間ドック内視鏡検査との同時検討から. ペプシノゲン法. 医学書院, 1998. 69-75.
 
5) 井上和彦, 他. Helicobacter pylori除菌治療後の血清ペプシノゲンおよび前庭部胃炎-6か月以上経過症例の検討-. 消化器科. 1996 ; 22 : 594-599.
 
6) 近藤隆則, 他. 中学生Helicobacter pylori検診と除菌治療-真庭市における3年間の成績-. 日本ヘリコバクター学会誌. 2017 ; 18 : 14-20.
 
7) Furuta T, et al. Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacer pylori. Am J Gastroenterol. 1997 ; 92 : 84-87.
 
P.119 掲載の参考文献
1) Kato M, et al. Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn. J Clin Oncol. 2010 ; 40 : 828-837.
PubMed
2) Uemura N, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 ; 345 : 784-789.
PubMed
3) 井田和徳, 他. 胃がんEMR後のサーベイランス. 胃と腸. 1998 ; 33 : 1687-1693.
 
4) 光永篤, 他. 早期胃がんEMR後のサーベイランス. 胃と腸. 1998 ; 33 : 1695-1703.
 
5) 横井千寿, 他. 胃がんEMR後の異時性多発を考える. 胃と腸. 2005 ; 40 : 1602-1608.
 
6) 細川治, 他. 胃がん内視鏡的切除後の遺残・多発癌発見を目指したサーバイランス. 胃と腸. 2005 ; 33 : 1623-1632.
 
7) Kobayashi M, et al. Self-limiting risk of metachronous gastric cancers after endoscopic resection. Digest Endosc. 2010 ; 22 : 169-173.
 
8) 高木國夫. 多発胃がん. 胃と腸. 1994 ; 29 : 625-626.
 
9) 三上哲夫, 他. 多発胃がん-病理学的立場から. 胃と腸. 1994 ; 29 : 627-632.
 
10) Uemura N, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997 ; 6 : 639-642.
PubMed
11) Fukase K, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomised controlled trial. Lancet. 2008 ; 372 : :392-397.
PubMed
12) Kato M. Metachronous gastric cancer risk after endoscopic resection of early gastric cancer and H. pylori status. J Gastroenterol. 2019 ; 54 : 478-479.
 
13) Choi J, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014 ; 12 : 793-800.
 
14) Choi JM, et al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention : a randomized controlled trial. Gastrointest Endosc. 2018 ; 88 : 475-485.
PubMed
15) Choi IJ, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018 ; 378 : 1085-1095.
PubMed
16) Yoon SB, et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors : a meta-analysis. Helicobacter. 2014 ; 19 : 243-248.
 
17) Jung DH, et al. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm : A meta-analysis. PLoS One. 2015 ; 10 : e0124725.
PubMed
18) Bang CS, et al. Helicobacter pylori eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. J Korean Med Sci. 2015 ; 30 : 749-756.
PubMed
19) Chen HN, et al. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia : evidence from a meta-analysis. Gastric Cancer. 2016 ; 19 : 166-175.
 
20) Rokkas T, et al. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017 ; 30 : 414-423.
 
21) Lee YC, et al. Association between Helicobacter pylori eradication and gastric cancer incidence : A systematic review and meta-analysis. Gastroenterology. 2016 ; 150 : 1113-1124.e5.
 
22) Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer : A systematic review and meta-analysis. Gastric Cancer. 2019 ; 22 : 435-445.
PubMed
23) Xiao S, et al. Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer : A systematic review and meta-analysis. J Gastroenterol. 2019 ; 54 : 226-237.
PubMed
24) Fan F, et al. Effects of eradicating Helicobacter pylori on metachronous gastric cancer prevention : a systematic review and meta-analysis. J Eval Clin Pract. 2020 ; 26 : 308-315.
PubMed
25) Zhao B, et al. Does Helicobacter pylori eradication reduce the incidence of metachronous gastric cancer after curative endoscopic resection of early gastric cancer : a systematic review and meta-analysis. J Clin Gastroenterol. 2020 ; 54 : 235-241.
PubMed
26) Take S, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer ; a prospective cohort study. J Gastroenterol. 2015 ; 50 : 638-644.
PubMed
27) IARC H. pylori working group. H. pylori eradication as a strategy for preventing gastric cancer. International agency for research on cancer (IARC Working Group Reports, No 8. 2014 : 8.
 
28) H. pylori感染の診断と治療のガイドライン 2016改訂版. 日本ヘリコバクター学会ガイドライン作成委員会. 先端医学社.
 
P.136 掲載の参考文献
1) Warren JR, et al. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983 ; 1 : 1273-1275.
PubMed
2) Uemura N, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997 ; 6 : 639-642.
PubMed
3) Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol. 2000 ; 35 Suppl 12 : 90-97.
 
4) Uemura N, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 ; 345 : 784-789.
PubMed
5) Fukase K, et al. Eradication of Helicobacter pylori after endoscopic resection of early gastric cancer reduced the incidence of metachronous gastric cancer. Lancet. 2008 ; 372 : 392-397.
 
6) Take S, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005 ; 100 : 1037-1042.
PubMed
7) Ogura K, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol. 2008 ; 42 : 279-283.
PubMed
8) Yanaoka K, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer. 2009 ; 125 : 2697-2703.
PubMed
9) Mabe K, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol. 2009 ; 15 : 4290-4297.
PubMed
10) Lee YC, et al. Association between Helicobacter pylori eradication and gastric cancer incidence : a systematic review and meta-analysis. Gastroenterology. 2016 ; 150 : 1113-1124.
PubMed
11) Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer : a systematic review and meta-analysis. Gastric Cancer. 2019 ; 22 : 435-445.
PubMed
12) Ford AC, et al. Helicobacter pylori eradication therapy to prevent gastric cancer : systematic review and meta-analysis. Gut. 2020 ; 69 : 2113-2121.
PubMed
13) Take S, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020 ; 55 : 281-288.
PubMed
14) Take S, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007 ; 42 Suppl 17 : 21-27.
 
15) Take S, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011 ; 46 : 318-324.
 
16) Take S, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer ; a prospective cohort study. J Gastroenterol. 2015 ; 50 : 638-644.
PubMed
17) Kamada T, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori : results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005 ; 21 : 1121-1126.
PubMed
18) 谷瑞希, 他. 病理学的にみた日本人胃がんの時代的変遷. 胃と腸. 2005 ; 40 : 27-36.
 
19) Masuda K, et al. Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradiation therapy. J Gastroenterol. 2019 ; 54 : 907-915.
PubMed
20) 水野元夫, 他. Helicobacter pylori除菌成功後に発見される胃がん-欠かせない除菌後フォローアップ-Helicobacter Research. 2009 ; 13 : 28-34.
 
21) 伊藤公訓. ポスト除菌時代の胃がん診療. 第14回日本ヘリコバクター学会学術集会抄録集 2008 : 160.
 
22) Take S, et al. Low incidence of esophageal adenocarcinoma after eradication of Helicobacter pylori in Japan. Clin Gastroenterol Hepatol. 2018 ; 16 : 1995-1996.
PubMed

III章 除菌後胃がんの特徴と内視鏡観察のコツ

P.150 掲載の参考文献
1) Uemura N, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 ; 345 : 784-789.
PubMed
2) Masuyama H, et al. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk. Digestion. 2015 ; 91 : 30-36.
PubMed
3) Sugimoto M, et al. Efficacy of the Kyoto classification of gastritis in identifying patients at high risk for gastric cancer. Intern Med. 2017 ; 56 : 579-586.
PubMed
4) 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類. 日本メディカルセンター, 2014.
 
5) Park YM, et al. Clinical risk assessment for gastric cancer in asymptomatic population after a health checkup : An individualized consideration of the risk factors. Medicine (Baltimore). 2016 ; 95 : e5351.
 
6) Koksal AS, et al. Is gastric xanthelasma an alarming endoscopic marker for advanced atrophic gastritis and intestinal metaplasia? Dig Dis Sci. 2016 ; 61 : 2949?2955.
 
7) Sekikawa A, et al. Gastric xanthelasma may be a warning sign for the presence of early gastric cancer. J Gastroenterol Hepatol. 2014 ; 29 : 951-956.
PubMed
8) Sekikawa A, et al. Gastric atrophy and xanthelasma are markers for predicting the development of early gastric cancer. J Gastroenterol. 2016 ; 51 : 35-42.
PubMed
9) Kitamura S, et al. Clinicopathological assessment of gastric xanthoma as potential predictive marker of gastric cancer. Digestion. 2017 ; 96 : 199-206.
PubMed
10) Shibukawa N, et al. Gastric xanthoma is a predictive marker for metachronous and synchronous gastric cancer. World J Gastrointest Oncol. 2017 ; 9 : 327-332.
PubMed
11) Kamada T, et al. Nodular gastritis with Helicobacter pylori infection is strongly associated with diffuse-type gastric cancer in young patients. Dig Endosc. 2007 ; 19 : 180-184.
 
12) Watanabe M, et al. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis. Int J Cancer. 2012 ; 131 : 2632-2642.
PubMed
13) Kamada T, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori : results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005 ; 21 : 1121-1126.
PubMed
14) 鎌田智有, 他. H. pylori除菌後に発見された胃癌症例の臨床病理学的特徴-多施設集計100症例の検討から. 胃と腸. 2008 ; 43 : 1810-1819.
 
15) 春間賢, 他. Helicobacter pylori除菌後10年以上経過して発見された胃癌症例の検討. 胃と腸. 2012 ; 47 : 1623-1629.
 
16) 加藤元嗣. ピロリ菌除菌による胃癌予防の経済効果に関する研究. 平成24年度総括・分担研究報告書. 厚生労働科学研究費補助金がん臨床研究事業, 2013.
 
17) Take S, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011 ; 46 : 318-324.
 
18) Shichijo S, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016 ; 84 : 618-624.
PubMed
19) Kodama M, et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol. 2013 ; 48 : 1249-1256.
PubMed
20) Toyoshima O, et al. Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication. Surg Endosc. 2017 ; 31 : 2140-2148.
PubMed
21) Sakitani K, et al. Gastric cancer diagnosed after Helicobacter pylori eradication in diabetes mellitus patients. BMC Gastroenterol. 2015 ; 15:143.
PubMed
22) Mori G, et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication : results of a large-scale, multicenter cohort study in Japan. Gastric Cancer. 2016 ; 19 : 911-918.
 
23) Shibukawa N, et al. Gastric xanthoma is a predictive marker for early gastric cancer detected after Helicobacter pylori eradication. Intern Med. 2019 ; 58 : 779-784.
PubMed
24) 鎌田智有, 他. Helicobacter pylori除菌後胃粘膜の内視鏡的変化「Helicobacter pylori除菌後に認められる胃粘膜所見の特徴」Helicobacter Research. 2015 ; 19 ; 16-22.
 
25) Nishikawa I, et al. Nodular gastritis in association with gastric cancer development before and after Helicobacter pylori eradication. JGH Open. 2018 ; 2 : 80-86.
PubMed
26) 永田豊, 他. Helicobacter pylori除菌後スキルス胃癌を呈した鳥肌胃炎の1例. 胃と腸. 2012 ; 47 : 1685-1694.
 
27) 安田真弓, 他. 鳥肌胃炎に対するHelicobacter pylori除菌治療の6年後に発見された未分化型早期胃癌の1例. 山口医学. 2015 ; 64, 47-51.
Medical*Online
28) 小寺徹, 他. 鳥肌胃炎除菌18ヵ月後に発見された未分化型胃癌の1例. 第24回日本ヘリコバクター学会学術集会プログラム・抄録集. 2018, 116.
 
29) 村尾高久, 他. 経鼻内視鏡にて発見された鳥肌胃炎除菌後未分化型早期胃癌の一例. 日消がん検診誌. 2018 ; 56, 165.
 
30) Take S, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020 ; 55 : 281-288.
PubMed
31) Kodama M, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012 ; 47 : 394-403.
PubMed
P.156 掲載の参考文献
1) Ono S, et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012 ; 86 : 59-65.
 
2) Masuyama H, et al. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk. Digestion. 2015 ; 91 : 30-36.
PubMed
3) Haneda M, et al. Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2013 ; 28 : 78-83.
PubMed
4) Yamamichi N, et al. Atrophic gastritis and enlarged gastric folds diagnosed by double-contrast upper gastrointestinal barium X-ray radiography are useful to predict future gastric cancer development based on the 3-year prospective observation. Gastric Cancer. 2016 ; 19 : 1016-1022.
 
5) Shibukawa N, et al. Gastric xanthoma is a predictive marker for early gastric cancer detected after Helicobacter pylori eradication. Intern Med. 2019 ; 58 : 779-784.
PubMed
6) Nisshikawa I, et al. Nodular gastritis in association with gastric cancer development before and after Helicobacter pylori eradication. JGH Open. 2018 ; 2 : 80-86.
PubMed
P.168 掲載の参考文献
1) Nawata Y, et al. Reversal phenomenon on the mucosal borderline relates to development of gastric cancer after successful eradiation of H. pylori. Journal of GHR. 2017 ; 6 : 1-6.
 
2) Nagata N, et al. Predictability of gastric intestinal metaplasia by mottled patchy erythema seen on endoscopy. Gastroenterol Res. 2011 ; 4 : 203-209.
 
3) 吉田将雄, 他. 腺境界 (atrophic border). 胃と腸. 2017 ; 52 : 590.
 
4) 中村恭一. 胃癌の構造 第3版. 医学書院, 2005.
 
5) 貝瀬満, 他. 背景胃粘膜・がん組織型に応じた早期胃癌内視鏡診断の基本. 消化器内視鏡. 2020 ; 32 : 25-40.
 
6) 鎌田智有, 他. Helicobacter pylori除菌後に発見された胃癌症例の臨床病理学的特徴-多施設集計計100例の検討から. 胃と腸. 2008 ; 43 : 1810-1819.
 
7) Shichijo S, et al. Characteristics and predictors of gastric cancer after Helicobacter pylori eradiation. World J Gastroenterol. 2018 ; 24 : 2163-2172.
 
8) Yamamoto K, et al. Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. Helicobacter. 2011 ; 16 : 210-216.
PubMed
9) Ito M, et al. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Aliment Pharmacol Ther. 2005 ; 559-566 : 21.
 
10) Muto M, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). Dig Endosc. 2016 ; 28 : 379-393.
PubMed
11) Kobayashi M, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradiation. J Gastroenterol. 2013 ; 48 : 1332-1342.
 
12) Saka A, et al. Endoscopic and histological features of gastric cancers after successful Helicobacter pylori eradiation therapy. Gastric Cancer. 2016 ; 19 : 524-530.
 
13) Kitamura Y, et al. Characteristic epithelium with low-grade atypia appears on the surface of gastric cancer after successful Helicobacter pylori eradication therapy. Helicobacter. 2014 ; 19 : 289-295.
 
P.174 掲載の参考文献
1) Sugano K, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 ; 64 : 1353-1367.
PubMed
2) 鎌田智有, 他. 除菌後発見胃癌の臨床的特徴-除菌後10年未満と10年以上で発見された胃癌の比較-. 胃と腸. 2016 ; 51 : 750-758.
 
3) Fukase K, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer : an open-label, randomised controlled trial. Lancet. 2008 ; 372 : 392-397.
PubMed
4) Matsuo T, et al. Gastric cancer development after Helicobacter pylori eradication therapy : A new form of gastric neoplasia. Digestion. 2012 ; 85 : 61-67.
PubMed
5) Take S, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer ; a prospective cohort study. J Gastroenterol. 2015 ; 50 : 638-644.
PubMed
6) Kodama M, et al. Endoscopic and immunohistochemical characteristics of gastric cancer with versus without Helicobacter pylori eradication. Digestion. 2018 ; 97 : 288-297.
PubMed
7) Maehata Y, et al. Characteristics of primary and metachronous gastric cancers discovered after Helicobacter pylori eradication : A multicenter propensity score-matched study. Gut Liver. 2017 ; 11 : 628-634.
PubMed
8) Horiguchi N, et al. Distinct clinic-pathological features of early differentiated-type gastric cancers after Helicobacter pylori eradication. Gastroenterol Res Pract. 2016 ; 2016 : 8230815.
PubMed
9) Ito M, et al. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Aliment Pharmacol Ther. 2005 ; 21 : 559?566.
 
10) Kotachi T, et al. Clinical significance of reddish depressed lesions observed in the gastric mucosa after Helicobacter pylori eradication. Digestion. 2018 ; 98 : 48-55.
PubMed
11) Hata K, et al. Gastric cancer with submucosal invasion after successful Helicobacter pylori eradication : a propensity score-matched analysis of patients with annual patient endoscopic survey. Digestion. 2019 ; 99 : 59-65.
PubMed
12) Kobayashi M, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol. 2013 ; 48 : 1332-1342.
PubMed
P.184 掲載の参考文献
1) Kamada T, et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 2015 ; 20 : 192-198.
PubMed
2) Kobayashi M, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol. 2013 ; 48 : 1332-1342.
PubMed
3) 鎌田智有. 第2章 胃炎の内視鏡所見-総論 : 春馬賢, 他. 胃炎の京都分類. 日本メディカルセンター, 2014 : 25-29.
 
4) Moribata H, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication. Dig Endosc. 2016 ; 28 : 434-442.
 
5) 小林正明, 他. 除菌後に発見された胃癌におけるNBI拡大内視鏡所見の特徴. 胃と腸. 2015 ; 50 : 289-299.
 
6) 小林正明, 他. 拡大内視鏡による胃癌の組織型の診断. 胃と腸. 2016 ; 51 : 622-633.
 
7) 吉村大輔, 他. Helicobacter pylori未感染胃癌・胃腫瘍の拡大内視鏡診断. 胃と腸. 2019 ; 4 : 234-245.
 
8) Horiuchi Y, et al. Diagnostic accuracy of demarcation of undifferentiated-type early gastric cancer after Helicobacter pylori eradication. J Gastroenterol. 2017 ; 52 : 1023-1030.
PubMed
9) Kodama M, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012 ; 47 : 394-403.
PubMed
10) Take S, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020 ; 55 : 281-288.
PubMed
P.194 掲載の参考文献
1) 矢田智之. 除菌後に発見される進行胃がんの特徴. 消化器内科 2020 ; 2 : 73-79.
 
2) 矢田智之, 他. H. pylori除菌後発見胃癌の特徴～深達度別の比較～. 日本消化器内視鏡学会雑誌. 2020 ; 62 : 1134.
 
3) Take S, et al. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication. J Gastroenterol. 2020 ; 55 : 281-288.
PubMed
4) 矢田智之, 他. 「胃炎の京都分類」を日常診療でいかに使うか-Helicobacter pylori感染症の現況と今後をふまえ-胃炎の京都分類の代表的所見 襞過形成. Helicobacter Research. 2016 ; 20 : 336-337.
 
5) Nishikawa I, et al. Nodular gastritis in association with gastric cancer development before and after Helicobacter pylori eradication. JGH Open. 2018 ; 2 : 80-86.
PubMed
6) 井上和彦, 他. 胃癌リスク診断 (ABC分類) の基本と問題点. 消化器内視鏡. 2012 ; 24 : 1659-1665.
Medical*Online
7) 牛島俊和, 他. 除菌後胃がん発生と遺伝子異常. 消化器内科. 2020 ; 2 : 88-95.
 
P.202 掲載の参考文献
1) 全国がん登録データ (2017) https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450173&tstat=000001133323
 
P.208 掲載の参考文献
1) Tsuda M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan Helicobacter. 2017 ; 22 : e12415.
 
2) Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer : a systematic review and meta-analysis. Meta-Analysis Gastric Cancer. 2019 ; 22 : 435-445.
PubMed
3) Ito M, et al. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Comparative Study Aliment Pharmacol Ther. 2005 ; 21 : 559-566.
 
4) Kobayash M, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol. 2013 ; 48 : 1332-1342.
 
5) Hata K, et al. Gastric cancer with submucosal invasion after successful Helicobacter pylori eradication : A propensity score-matched analysis of patients with annual patient endoscopic survey. Digestion. 2019 ; 99 : 59-65.
PubMed
6) Kawai T, et al. Evaluation of gastric cancer diagnosis using new ultrathin transnasal endoscopy with narrow-band imaging : preliminary study. Gastroenterol Hepatol. 2014 ; 29 Suppl 4 : 33-36.
PubMed
7) Yao K, et al. Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy. 2009 ; 41 : 462-467.
PubMed
8) Muto M, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). Dig Endosc. 2016 ; 28 : 379-393.
PubMed
P.214 掲載の参考文献
1) Kobayashi M, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol. 2013 ; 48 : 1332-1342.
PubMed
2) 小野尚子, 他. H. pylori除菌後, 感染既往のある胃癌治療後のサーベイランス. 消化器内視鏡. 2018 ; 30 : 85-89.
Medical*Online
3) 久保雅裕, 他. 新しいIEEの原理と画像Blue 1ASER imagingを搭載した内視鏡システム-LASEREO. Intestine. 2013 ; 17 : 297-302.
 
4) Kitagawa Y, et al. Comparison of endoscopic visibility and miss rate for early gastric cancers after Helicobacter pylori eradication with white-light imaging versus linked color imaging. Dig Endosc. 2020 ; 32 : 769-777.
PubMed
5) Yasuda T, et al. Benefi ts of linked color imaging for recognition of early differentiated-type gastric cancer : in comparison with indigo carmine contrast method and blue laser imaging. Surg Endosc. 2020. doi : 10.1007/S00464-020-07706-1.
 
6) Ono S, et al. Accuracies of endoscopic diagnosis of Helicobacter pylori-Gastritis : Multicenter prospective study using white light imaging and linked color imaging. Digestion. 2020 ; 101 : 624-630.
PubMed
7) Pimentel-Nunes P, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II) : European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 ; 51 : 365-388.
 
8) 春間賢, 監. 加藤元嗣, 他編. 胃炎の京都分類 改訂第2版. 2018 : 35-38.
 
9) Song J, et al. Meta-analysis : Narrow band imaging for diagnosis of gastric intestinal metaplasia. PLoS One. 2014 ; 9 : e94869.
PubMed
10) Ono S, et al. Lavender color in linked color imaging enables noninvasive detection of gastric intestinal metaplasia. Digestion. 2018 ; 98 : 222-230.
PubMed
11) 川田研郎, 他. 消化管がん患者を対象として新画像強調処理 (LCI) を用いた上部消化管腫瘍性病変の検出能に関するランダム化試験. Gastroenterological Endoscopy. 2019 ; 61 (supple 1) : 893.
 
12) Ono S, et al. Linked color imaging enhances gastric cancer in gastric intestinal metaplasia. Dig Endosc. 2017 ; 29 : 230-231.
PubMed
13) 小野尚子, 他. 精密診断 ; 量的診断 (staging) -BLIを中心に. 消化器内視鏡. 2017 ; 29 : 2178-2185.
Medical*Online
P.222 掲載の参考文献
1) Kodama M, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012 ; 47 : 394-403.
PubMed
2) Kimura K, et al. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969 ; 1 : 87-97.
 
3) Kanzaki H, et al. Comprehensive investigation of areae gastricae pattern in gastric corpus using magnifying narrow band imaging endoscopy in patients with chronic atrophic fundic gastritis. Helicobacter. 2012 ; 17 : 224-231.
PubMed
4) Muto M, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). Dig Endosc. 2016 ; 28 : 379-393.
PubMed
5) Kobayashi M, et al. Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol. 2013 ; 48 : 1332-1342.
PubMed
6) 小林正明, 他. 除菌後に発見された胃癌におけるNBI拡大内視鏡所見の特徴. 胃と腸. 2015 ; 50 : 289-299.
 
7) Saka A, et al. Endoscopic and histological features of gastric cancers after successful Helicobacter pylori eradication therapy. Gastric Cancer. 2016 ; 19 : 524-530.
 
8) 小林正明, 他. 先進的診断内視鏡によるH. pylori除菌後胃癌診断. 日消誌. 2016 ; 113 : 235-244.
Medical*Online
9) Kobayashi M, et al. Therapeutic or spontaneous Helicobacter pylori eradication can obscure magnifying narrow-band imaging of gastric tumors. Endosc Int Open. 2016 ; 4 : E665-672.
 
10) Yagi K, et al. Green epithelium revealed by narrow-band imaging (NBI) : a feature for practical assessment of extent of gastric cancer after H. pylori eradication. Endosc Int Open. 2018 ; 6 : E1289-1295.
PubMed

IV章 未感染胃がん、その他の内視鏡所見

P.230 掲載の参考文献
1) 伊藤公訓, 他. Helicobacter pylori陰性胃癌の定義と判定. 胃と腸. 2014 ; 49 : 835-839.
 
2) Kiso M, et al. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test : a multicenter study. Gastric Cancer. 2017 ; 20 : 764-771.
 
3) Uemura N, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 ; 345 : 784-789.
PubMed
4) Matsuo T, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011 ; 16 : 415-419.
PubMed
5) Yorita N, et al. Potential of Helicobacter pylori-uninfected signet ring cell carcinoma to invade the submucosal layer. J Gastroenterol Hepatol. 2019 ; 34 : 1955-1962.
 
6) Horiuchi Y, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer : comparison with Helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016 ; 19 : 160-165.
 
7) Funakoshi T, et al. Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer. Gastric Cancer. 2019 ; 22 : 892-898.
 
8) Kiso M, et al. Clinical and genomic characteristics of mucosal signet-ring cell carcinoma in Helicobacter pylori-uninfected stomach. BMC Gastroenterol. 2020 ; 20 : 243.
PubMed
P.237 掲載の参考文献
1) Tsukamoto T, et al. Gastric adenocarcinoma with chief cell differentiation. Pathol Int. 2007 ; 57 : 517-522.
PubMed
2) Ueyama H, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type) proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010 ; 34 : 609-619.
PubMed
3) Singhi AD, et al. Gastric adenocarcinoma with chief cell differentiation : a proposal for reclassification as oxyntic gland polyp/adenoma. Am J Surg Pathol. 2012 ; 36 : 1030-1035.
PubMed
4) Benedict MA, et al. Gastric adenocarcinoma of the fundic gland type : update and literature review. Am J Clin Pathol. 2018 ; 149 : 461-73.
PubMed
5) 日本胃癌学会, 編. 胃癌取扱い規約 第15版. 金原出版, 2017.
 
6) WHO Classification of Tumours of the Digestive System, 5th edition 2019.
 
7) 上山浩也, 他. 早期胃癌. 特殊な組織型を呈する早期胃癌, 4) 胃底腺型胃癌. 胃と腸. 2018 ; 53 : 753-767.
 
8) 上山浩也, 他. 早期胃癌の範囲診断 up to date. 早期胃癌の範囲診断-範囲診断困難例とその臨床対応, 4) 胃型の腺癌. 胃と腸. 2020 ; 55 : 67-82.
 
9) 上山浩也, 他. 胃底腺癌, 消化管症候群. 別冊日本臨牀. 2019 ; 9 : 241-246.
 
10) 田邉寛, 他. 胃底腺型胃癌の病理組織学的特徴. 胃と腸. 2015 ; 50 : 1469-1479.
 
11) 八尾隆史, 他. 新しいタイプの胃癌-胃底腺型胃癌-臨床病理学的特徴と発育進展様式および悪性度. 胃と腸. 2010 ; 45 : 1192-1202.
 
12) Ueo T, et al. Gastric adenocarcinoma of fundic gland type with unusual behavior. Dig Endosc. 2014 ; 26 : 291-297.
 
13) Okumura Y, et al. Gastric adenocarcinoma of fundic gland type with aggressive transformation and lymph node metastasis : A case report. J Gastric Cancer. 2018 ; 18 : 409-416.
PubMed
14) Kai K, et al. Gastric adenocarcinoma of fundic gland type with signet-ring cell carcinoma component : A case report and review of the literature. World J Gastroenterol. 2018 ; 24 : 2915-2920.
PubMed
15) Ueyama H, et al. Gastric adenocarcinoma of the fundic gland type (chief cell predominant type). Endoscopy. 2014 ; 46 : 153-157.
PubMed
16) 上山浩也, 他. 早期胃癌, 特殊な組織型を呈する早期胃癌, 4) 胃底腺型胃癌. 胃と腸. 2018 ; 53 : 753-767.
 
17) 上山浩也, 他. 手技の解説 胃底腺型胃癌の診断のコツ. Gastroenterol Endosc. 2016 ; 58 : 1169-1177.
 
18) Yatagai N, et al. Clinicopathological and endoscopic features of raspberry-shaped gastric cancer in Helicobacter pylori-uninfected patient. Digestion, 2020 in press.
 
19) Yao K, et al. Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy. 2009 ; 41 : 462-467.
PubMed
20) Muto M, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). Dig. Endosc. 2016 ; 28 : 379-393.
PubMed
21) 上山浩也, 他. 消化器癌の拡大内視鏡診断, 胃底腺型胃癌の拡大内視鏡診断. 臨床消化器内科. 2017 ; 32 : 1701-1711.
 
22) 上山浩也, 他. 胃底腺型胃癌の臨床的特徴. 拡大内視鏡所見を中心に-胃底腺型胃癌のNBI併用拡大内視鏡診断. 胃と腸. 2015 ; 50 : 1533-1547.
 
23) 上山浩也, 他.胃炎と鑑別困難な胃癌. 胃底腺型胃癌 (内視鏡と病理). 拡大内視鏡. 日本メディカルセンター, 2014. 73-79.
 
24) 藤原昌子, 他. 胃底腺型胃癌と胃底腺粘膜型胃癌の通常内視鏡・NBI併用拡大内視鏡所見. 胃と腸. 2015 ; 50 : 1548-1558.
 
25) 藤澤貴史, 他. 胃型分化型腺癌に特徴的なNarrow band imaging (NBI) 拡大像が観察された胃底腺型胃癌の1例. Gastrointest endosc. 2011 ; 53 : 3769-3775.
 
26) 上山浩也, 他. 手技の解説. 胃底腺型胃癌の診断のコツ. Gastroenterol Endosc. 2016 ; 58 : 1169-1177.
 
27) 上山浩也, 他. ピロリ陰性 (未感染) 胃癌の現状について. 日本ヘリコバクター学会誌. 2019 ; 20 : 103-111.
Medical*Online
28) 上山浩也, 他. 早期胃癌の範囲診断 up to date. 早期胃癌の範囲診断-範囲診断困難例とその臨床的対応, 胃型の腺癌. 胃と腸. 2020 ; 55 : 67-82.
 
29) 磯野功明, 他. 長期間経過を追えた微小胃底腺型胃癌の1例. Gastroenterol Endosc. 2015 ; 57 : 2639-2645.
 
30) Sato Y, et al. Twelve-year natural history of a gastric adenocarcinoma of fundic gland type. Clin J Gastroenterol. 2016 ; 9 : 345-51.
PubMed
31) Abe T, et al. Long-term follow-up of gastric adenocarcinoma with chief cell differentiation using upper gastrointestinal tract endoscopy. Intern Med. 2013 ; 52 : 1585-8.
PubMed
P.247 掲載の参考文献
1) Matsuo T, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011 ; 16 : 415-459.
PubMed
2) Ono S, et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012 ; 86 : 59-65.
 
3) Yoon H, et al. Helicobacter pylori-negative gastric cancer in South Korea : incidence and clinicopathologic characteristics. Helicobacter. 2011 ; 16 : 382-388.
PubMed
4) Gertler R, et al. How to classify adenocarcinomas of the esophagogastric junction : As esophageal or gastric cancer?. Am J Surg Pathol. 2011 ; 35 : 1512-1522.
 
5) Yamada M, et al. Different histological status of gastritis in superficial adenocarcinoma of the esophagogastric junction. Jpn J Clin Oncol. 2014 ; 44 : 65-71.
PubMed
6) 新井富生, 他. 食道胃接合部腺癌の病理学的特徴. 胃と腸. 2015 ; 50 : 1109-1117.
 
7) Tsujiura M, et al. Liquid biopsy of gastric cancer patients : circulating tumor cells and cell-free nucleic acids. World J Gastroenterol. 2014 ; 28 : 3265-3286.
 
P.254 掲載の参考文献
1) Amy EN. Fenoglio-Preiser's Gastrointestinal Pathology. 4th. Wolters Kluwer, 2017.
 
2) Park DY, et al. Adenomatous and foveolar gastric dysplasia : distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol. 2008 ; 32 : 524-533.
PubMed
3) Shibagaki K, et al. Gastric foveolar-type adenomas endoscopically showing a raspberry-like appearance in the Helicobacter pylori-uninfected stomach. Endosc Int Open. 2019 ; 7 : E784-791.
PubMed
4) Horiuchi Y, et all. Study on clinical factors involved in Helicobacter pylori-uninfected, undifferentiated-type early gastric cancer. Digestion. 2017 ; 96 : 213-219.
 
5) 柴垣広太郎, 他. 特集 胃癌診断を極める「H. pylori未感染胃粘膜に生じるラズベリー様腺窩上皮型胃癌」. 消化器内視鏡. 2020 ; 32 : 97-105.
 
6) Serra S, et al. Gastric foveolar dysplasia : A survey of reporting habits and diagnostic criteria. Pathology. 2017 ; 49 : 391-396.
PubMed
P.257 掲載の参考文献
1) Shiratori S, et al. Two cases of chronic gastritis with non-Helicobacter pylori Helicobacter infection. Intern Med. 2016 ; 55 : 1865-1869.
PubMed
2) Goji S, et al. Helicobacter suis-infected nodular gastritis and a review of diagnostic sensitivity for Helicobacter heilmannii-like organisms. Case Rep Gastroenterol. 2015 ; 9 : 179-187.
 
3) Jie L, et al. Prevalence of coinfection with gastric non-Helicobacter pylori Helicobacter (NHPH) apecies in Helicobacter pylori-infected patients srffering from gastric disease in Beijing, China. Helicobacter. 2015 ; 20 : 284-290.
 
4) Nakamura M, et al. PCR analysis and specific immunohistochemistry revealing a high prevalence of non-Helicobacter pylori Helicobacters in Helicobacter pylori-negative gastric disease patients in Japan : High susceptibility to an Hp eradication regimen. Helicobacter 2020 ; 25 : e12700.
 
5) Takigawa H, et al. Helicobacter suis infection is associated with nodular gastritis-like appearance of gastric mucosa-associated lymphoid tissue lymphoma. Cancer Med. 2019 ; 8 : 4370-4379.
PubMed
6) Overby A, et al. Prevalence of gastric Non-Helicobacter pylori-Helicobacters in Japanese patients with gastric disease. Digestion. 2017 ; 95 : 61-66.
PubMed
P.267 掲載の参考文献
1) Strickland RG, et al. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis. 1973 ; 18 : 426-440.
PubMed
2) Kalkan C, et al. Polyautoimmunity in autoimmune gastritis. Eur J Intern Med. 2016 ; 31 : 79-83.
PubMed
3) 寺尾秀一, 他. D群のほとんどは,「高度の萎縮とI. M. のためにH. pyloriが駆逐された」群ではない. 日本ヘリコバクター学会誌. 2013 ; 14 : 5-14.
Medical*Online
4) Furuta T, et al. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther. 2018 ; 48 : 370-377.
PubMed
5) 青木利佳, 他. 内視鏡検診におけるA型胃炎. 胃と腸. 2019 ; 54 : 1046-1052.
 
6) Terao S, et al. Multicenter study of autoimmune gastritis in Japan : Clinical and endoscopic characteristics. Dig Endosc. 2020 ; 32 : 364-372.
PubMed
7) 丸山保彦, 他. A型胃炎の画像所見 通常内視鏡所見を中心に. 胃と腸. 2019 ; 54 : 998-1009.
 
8) Lahner E, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009 ; 104 : 2071-2079.
PubMed
9) 角直樹, 他. 高度萎縮胃炎におけるA型胃炎の頻度とH. pylori感染との関連. 日本消化管学会雑誌. 2020 ; 4 (Suppl) : 256.
 
10) 渡辺英伸. A型胃炎の組織診断基準試案. Gastroenterol Endosc. 2019 ; 61 (Suppl. 1) : 1028.
 
11) Hsing A, et al. Pernicious anemia and subsequent cancer. A population-based cohort study, Cancer. 1993 ; 71 : 745-750.
 
12) Nehme F, et al. Autoimmune metaplastic atrophic gastritis and association with neuroendocrine tumors of the stomach. Clin J Gastroenterol. 2020 ; 13 : 299-307.
PubMed
13) 日本神経内分泌腫瘍研究会, 編. CQ1-1 胃NETに対する内視鏡的切除の適応および推奨される手技は何か? 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン 第2版. 金原出版, 2019. 103-105.
 
14) Weise F, et al. Gastric cancer in autoimmune gastritis : A case-control study from the German centers of the staR project on gastric cancer research. United European Gastroenterol J. 2020 ; 8 : 175-184.
 
15) 八板弘樹, 他. A型胃炎に合併した胃癌症例の特徴. 胃と腸. 2019 ; 54 : 1025-1034.
 
16) Yamamoto K, et al. Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. Helicobacter. 2011 ; 16 : 210-216.
PubMed
17) Mizoshita T, et al. Gastric and intestinal phenotypes and histogenesis of advanced glandular stomach cancers in carcinogen-treated, Helicobacter pylori-infected Mongolian gerbils. Cancer Sci. 2006 ; 97 : 38-44.
PubMed

書評

最近チェックした商品履歴

Loading...